Rhinology最新文献

{"title":"Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREA.","authors":"G Verstappen, X Bertels, R O Al-Lehebi, B M Alim, N H Alotaibi, S Alsaleh, V Backer, M Bernal-Sprekelsen, B S Bleier, Y Chan, D M Conti, M E Cornet, E de Corso, P Gevaert, J Hagenmann, J Han, C H Hopkins, M Jeseňák, E Khaleva, S Lau, S E Lee, V J Lund, A T Peters, C Pipolo, K F Rabe, G Scadding, S Schneider, B A Senior, P K Smith, M E Wechsler, W J Fokkens, P W Hellings","doi":"10.4193/Rhin26.419","DOIUrl":"https://doi.org/10.4193/Rhin26.419","url":null,"abstract":"<p><p>Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice (1). Real-world studies confirm their effectiveness beyond controlled clinical trial settings and highlight biologics as a major therapeutic advance for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and eosinophilic chronic obstructive pulmonary disease (COPD) (2-4). Biologics have been shown to significantly improve disease control and potentially enable the achievement of new treatment goals, including clinical and complete remission (5).</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior internal carotid artery embolization to optimize oncological and surgical outcomes in salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma.","authors":"H Xu, W Li, H Zhang, K Xue, Y Gu, H Li, Q Liu, D Wang, Q Liu","doi":"10.4193/Rhin26.296","DOIUrl":"https://doi.org/10.4193/Rhin26.296","url":null,"abstract":"<p><p>BACKGROUND Salvage endoscopic nasopharyngectomy (SEN) for recurrent nasopharyngeal carcinoma (rNPC) with internal carotid artery (ICA) involvement carries prohibitive risks of catastrophic hemorrhage and incomplete resection. This study aims to evaluate the efficacy and safety of preoperative ICA embolization.</p><p><strong>Methods: </strong>Between January 2006 and December 2022, 535 patients who underwent SEN for rNPC were retrospectively screened. Among 140 patients with radiological ICA involvement, 114 eligible patients were identified after predefined exclusions. Propensity score matching (1:1) yielded 50 well-balanced pairs comparing SEN with preoperative ICA embolization versus SEN alone. Endpoints included overall survival, progression-free survival, R0 resection rate and the incidence of treatment-related complications.</p><p><strong>Results: </strong>The embolization group demonstrated a statistically significant improvement in progression-free survival (PFS) compared to the non-embolization group. While overall survival (OS) showed a favorable clinical trend for the embolization cohort, it did not reach statistical significance. Preoperative embolization facilitated a significantly higher R0 resection rate and drastically reduced the incidence of fatal ICA rupture. Swimming plot analysis revealed prolonged disease stability and enhanced responsiveness to subsequent salvage therapies in the embolization cohort. Additionally, this cohort exhibited lower incidence of postoperative cerebral ischemia, while other treatment-related general adverse events tended to be more frequent, especially in dysphagia.</p><p><strong>Conclusion: </strong>Preoperative ICA embolization is a transformative and safe adjunctive strategy that significantly improves PFS and local oncological control for patients with rNPC involving the ICA.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy, completeness and hallucinations in large language model generated statements and references for common rhinologic disorders.","authors":"I Margulis, M A M Slim, E C Sommer, Y AAlammar, A B Kassam, S Khalife, L Macias-Valle, D D Sommer","doi":"10.4193/Rhin26.460","DOIUrl":"https://doi.org/10.4193/Rhin26.460","url":null,"abstract":"<p><p>Large language models (LLMs) are increasingly adopted for medical documentation, clinical decision-making, and scientific writing. Although these applications demonstrated impressive capabilities, concerns persist regarding their accuracy, fabricated references, and ethical implications (1-3). The Massive Multitask Language Understanding (MMLU) test was introduced as a comprehensive benchmark to evaluate how well LLMs perform across a diverse range of tasks (4). This prospective comparative two part study evaluated the accuracy and completeness of ChatGPT (CGPT)-3.5-generated 100 word summaries of four common rhinologic disorders (epistaxis, allergic rhinitis, odontogenic sinusitis, and chronic rhinosinusitis) including background, investigations, and magement as assessed by international rhinology society members. Furthermore, we evaluated the accuracy of references generated by contemporary LLM versions for the same prompts (CGPT-5 thinking (5), non-thinking (6), Claude Sonnet 4.5 non-thinking (6) and Gemini 2.5 (7)). Otolaryngologists evaluated each statement using standardized scales for accuracy, completeness, and overall reference quality.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New CRS control tests: development and validation by EUFOREA.","authors":"D M Conti, W J Fokkens, G K Scadding, V Backer, S Lau, X Bertels, K Aanaes, M P Aguilera Quezada, A Alani, I Alobid, E Anisman, Y Chan, J Constantinidis, M Corbò, M Cornet, E J Correa, L M D Auria, E de Corso, A Del Cuvillo, M Doulaptsi, A García-Lliberós, F García Río, P Gevaert, J Han, J Lee, K Limage, G Liva, D R Lobo, A Manole, F Manole, F Mariño-Sanchez, J Maza-Solano, C Montuori, R Moreno-Luna, X I Mota Rojas, G B Patel, A Peters, E Prokopakis, S Quirce, D Ramdhani, S Reitsma, A Sánchez Barrueco, A Santamaría-Gadea, S Sánchez Gómez, T Sarafidou, S Snoeks, W Thorley, E Toskala, M Tucciarone, G Verstappen, J M Villacampa Aubá, I M Villarreal Patiño, M Wagenmann, L M Wang, C Almansa, A B Gandhi, S D Nash, A Radwan, Z Wang, A Belmans, P W Hellings","doi":"10.4193/Rhin26.139","DOIUrl":"https://doi.org/10.4193/Rhin26.139","url":null,"abstract":"<p><strong>Background: </strong>Measuring control in Chronic Rhinosinusitis (CRS) is important in clinical evaluation. We developed and validated 2 new tests for the evaluation of control in CRS, the 6-item CRS Control Test (CCT) and the 14-item CRS Patient Control Test (CPCT) and investigated their correlations with existing tools.</p><p><strong>Methods: </strong>An international survey was conducted in 1,102 CRS patients in 19 centres in 7 countries using a questionnaire including the newly developed CCT and CPCT, VAS scores for CRS severity and control, the EPOS control test (EPOSCT), the Sino-Nasal Outcome Test 22 (SNOT-22) and the Patient Global Assessment Tool (PGAT). We evaluated convergent and discriminative validity, internal consistency and cross-cultural validity. Furthermore, we performed an Item Response Theory (IRT) analysis and determined cut-off points for CCT and CPCT. Sub-analyses were performed for CRS patients with and without nasal polyps.</p><p><strong>Results: </strong>Both CCT (0-24) and CPCT (0-56) demonstrated a high correlation with SNOT-22 and the PGAT. Moderate correlations were observed for all other comparisons. Both tests showed good internal consistency, discriminative validity and cross-cultural validity. We propose for CCT ≤15 to indicate uncontrolled, 16-19 partially controlled, and ≥20 well controlled disease. For the CPCT we propose ≥22 for uncontrolled, 13-21 for partially controlled and ≤12 for well controlled disease.</p><p><strong>Conclusion: </strong>The brief CCT and the longer CPCT are new CRS control tests that show moderate to high correlations with existing tools. Both instruments demonstrated good psychometric properties and therefore can be recommended for use in clinical practice and research.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery and/or biologics in chronic rhinosinusitis with nasal polyps: EUFOREA/EPOS consensus paper.","authors":"E de Corso, P W Hellings, W J Fokkens, C Hopkins, V J Lund, C Montuori, J Mullol, X Bertels, V Backer, E Pasquini, B S Bleier, C Pipolo, M Wagenmann, M Bernal-Sprekelsen, M Cornet, D M Conti, P Gevaert, R Harvey, J K Han, L Klimek, R C Kern, B N Landis, S Lee, I Alobid, A U Luong, S Reitsma, S Schneider, G K Scadding, A R Sedaghat, B Senior, A V Thamboo, K C Welch, Y Chan, J Constantinidis, A Bader, N H AlOtaibi, S Alsaleh, M Al-Ahmad, A T Peters","doi":"10.4193/Rhin26.064","DOIUrl":"https://doi.org/10.4193/Rhin26.064","url":null,"abstract":"<p><p>The therapeutic landscape of chronic rhinosinusitis with nasal polyps (CRSwNP) has rapidly evolved over the past 6 years with the arrival of biologics, prompting a re-evaluation of the traditional stepwise management centred on corticosteroids and endoscopic sinus surgery (ESS). Although both ESS and biologics have proven efficacy, the optimal sequence, extent and timing of ESS relative to biologics remains a matter of debate. The international multidisciplinary panel of experts of EUFOREA/EPOS reached consensus on the aims, indications, timing, and therapeutic positioning of ESS, and biologics in CRSwNP. Evidence from pivotal RCTs, real-life studies and recent guidelines was critically reviewed. Consensus statements were drafted and refined through multiple rounds of discussion and voting. This EUFOREA/EPOS report provides key definitions and clinical criteria for ESS and biologics particiin CRSwNP, offering a unified framework for personalized, evidence-based care with the aim to achieve the best outcomes for patients. The expert group agreed that patients with diffuse disease should have at least a primary complete ESS, that concurrent initiation of sinus surgery and biologic therapy is not recommended with current evidence, and the indication for biologic therapy as established by earlier guidelines were enforced. It was emphasized that with the current knowledge on side effects of systemic corticosteroids, their long-term use is no longer accepted especially where biologics are available. By emphasizing complementary and disease-modifying effects of novel care strategies, this initiative aims at optimizing outcomes across the entire airway continuum in line with EPOS/EUFOREA's mission.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV detection by in situ hybridisation in sinonasal inverted papilloma and squamous cell carcinoma.","authors":"D Ginström, M Lundberg, J Hagström, C Haglund, E Auvinen, L M Aaltonen, S Viitasalo","doi":"10.4193/Rhin26.397","DOIUrl":"https://doi.org/10.4193/Rhin26.397","url":null,"abstract":"<p><p>Dear Editor: Sinonasal inverted papilloma (SNIP) is a rare benign but locally aggressive tumour with an annual incidence of approximately 0.5-1.5/100 000, accounting for 4.7% of all sinonasal tumours. SNIP may recur and can transform into sinonasal squamous cell carcinoma (SNSCC) (1). Human papillomavirus (HPV) has been linked to SNIP recurrence and malignant progression, with a meta-analysis reporting the incidence of HPV in SNIP as 16.9% (2). This aligns with the results of our previous prospective study (17.8%), showing that the presence of HPV DNA was associated with SNIP recurrence in 90 patients undergoing surgery (3).</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parosmia is associated with impaired quality of life independent of olfactory function and depressive symptoms.","authors":"A Lein, P Suppinger, B Renner, C A Müller, D T Liu","doi":"10.4193/Rhin25.711","DOIUrl":"https://doi.org/10.4193/Rhin25.711","url":null,"abstract":"<p><strong>Background: </strong>Parosmia is a qualitative olfactory disorder that frequently occurs after infection. Although it often co-exists with partially preserved olfactory function, it can substantially impair quality of life (QoL). The interplay between qualitative and quantitative olfactory dysfunction (OD), and their affective burden, remains unclear. This study examined the specific contribution of parosmia to olfaction-related QoL within a psychophysical-psychological framework.</p><p><strong>Methods: </strong>In this cross-sectional study, 348 patients with OD underwent assessment using the Sniffin' Sticks test (TDI), the Questionnaire of Olfactory Disorders - Positive and Negative Statements (QOD-NS and QOD-PS), and the PHQ-2 for depressive symptoms. Adjusted linear regression models tested main and interaction effects, followed by depression-adjusted analysis.</p><p><strong>Results: </strong>Patients with parosmia were younger and had higher TDI scores than patients without parosmia. Parosmia was associated with poorer olfaction-related QoL (higher QOD-NS) and reduced coping ability (lower QOD-PS). In additive models, parosmia predicted higher QOD-NS and lower QOD-PS, while TDI predicted lower QOD-NS but was not related to QOD-PS. Depressive symptoms were strongly associated with poorer olfaction-related QoL and substantially increased the explained variance of the models. However, after adjustment for depressive symptoms, parosmia remained an independent predictor of both QOD-NS and QOD-PS. Across TDI categories, olfaction related QoL differed by parosmia status, although no interaction between TDI and parosmia was observed.</p><p><strong>Conclusion: </strong>Parosmia represents a distinct and clinically relevant burden on olfaction related QoL that is not explained by quantitative olfactory dysfunction or depressive symptoms. Understanding this independent burden is critical for targeted clinical management.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between chronic obstructive pulmonary disease and chronic rhinosinusitis: a longitudinal follow-up study using a national health insurance database.","authors":"M W Park, H J Jung, H G Choi, J H Wee","doi":"10.4193/Rhin26.130","DOIUrl":"10.4193/Rhin26.130","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to examine whether chronic obstructive pulmonary disease (COPD) is associated with the subsequentdevelopment of chronic rhinosinusitis (CRS) among Korean adults.</p><p><strong>Methodology: </strong>Using the 2002â€\"2019 Korean National Health Insurance database, we conducted a retrospective cohort study. Individuals with COPD, definted by relevant ICD-10 codes recorded on at least two occasions together with at least two prescriptions for COPD-related medicines (n=615,706), were matched with control participants (n=2,184,000) by age, sex, income, and region of residence. The incidence of CRS with and without nasal polyps was evaluated in both COPD and control groups. Hazard ratios (HRs) were estimated using stratified Cox proportional hazards models, and prespecified subgroup analyses were conducted.</p><p><strong>Results: </strong>The incidence rate of CRS was higher in patients with COPD than in control participants. After adjustment, the HR for CRS was significantly higher in the COPD group compared with the control group. Likewise, the HRs for CRS with nasal polyps and CRS without nasal polyps were also significantly higher in the COPD group than in the control group. Statistical significance was observed in all subgroups according to age, sex, income, and region of residence. Kaplanâ€\"Meier analyses showed a higher cumulative incidence in participants with COPD.</p><p><strong>Conclusions: </strong>In this nationwide Korean cohort, COPD was associated with a higher incidence of CRS, both with and without nasal polyps.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"636-646"},"PeriodicalIF":5.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing timing of cerebrospinal fluid leak after endoscopic skull base surgery: a multicenter study.","authors":"A A Halderman, M Z Cheng, A Abiri, K E Daniels, V Pandrangi, A D Workman, S Chung, S L Barnett, N D Adappa, G Choby, P A Gardner, M Geltzeiler, J N Palmer, C H Snyderman, E W Wang, G A Zenonos, E C Kuan","doi":"10.4193/Rhin25.695","DOIUrl":"10.4193/Rhin25.695","url":null,"abstract":"<p><strong>Introduction: </strong>Considerable work has been done to delineate risk factors for cerebrospinal fluid (CSF) leak after endoscopic skull base surgery (ESBS). Little work has been done to evaluate factors that influence the timing of CSF leaks after ESBS. The timing of when CSF leaks occur may have important implications on postoperative precautions and managing the underlying etiology. The aim of this multi-institutional study was to evaluate postoperative CSF leaks after ESBS to determine timing of occurrence and factors that influence when leaks occur.</p><p><strong>Methods: </strong>Data were collected retrospectively on patients diagnosed with CSF leak after ESBS at 5 institutions from 2010 to 2024. Variables including patient demographics, tumour and defect dimensions, defect location, reconstruction, timing of CSF leak, management of leak, and rates of meningitis were collected.</p><p><strong>Results: </strong>A total of 184 patients were analysed. The median postoperative day (POD) when CSF leak occurred was 7. Prior radiation, BMI less then 25, recurrent tumours, large defect size, defects located in the clivus, and CSF diversion were all associated with delays in presentation of postoperative CSF leak (all p less then 0.05). On multivariate analysis, BMI and history of radiation retained significance in association with delayed CSF leak. Timing of leak also appeared to be impacted by the number of, and specific layers used in reconstruction.</p><p><strong>Conclusions: </strong>Several factors were found to impact the timing of CSF leak after ESBS including patient, intraoperative, and postoperative factors. Understanding timing of postoperative CSF leaks may provide insights for prevention and secondary management.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"658-668"},"PeriodicalIF":5.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148043583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab in chronic rhinosinusitis without nasal polyps: randomized phase 2 trial (ORION).","authors":"S E Lee, A T Peters, P Gevaert, J K Han, C Bachert, F Moreira da Silva, A Rosenbluut, C C Hu, J Maloney, P Caferra, A Michalak, A P Fontenot, L B Robinson, N A Phadke","doi":"10.4193/Rhin25.660","DOIUrl":"10.4193/Rhin25.660","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis (CRS) is often driven by type 2 inflammation and is characterized by nasal obstruction/ discharge, facial pain/pressure, and/or reduced smell, either with or without nasal polyps (CRSwNP or CRSsNP).</p><p><strong>Objective: </strong>To test whether dupilumab improves radiographic features in CRSsNP.</p><p><strong>Methods: </strong>ORION (NCT04678856), a phase 2, randomized, multicenter, double blind, placebo-controlled study, assessed dupilumab efficacy and safety in adults with uncontrolled CRSsNP. Patients were randomized 1:1 to dupilumab or placebo for 24 to 52 weeks. Endpoints included changes from baseline at week 24 in Lund-Mackay computed tomography (LMK-CT) score (dupilumab only [primary] and vs placebo [secondary]), sinus Total Symptom Score (sTSS), University of Pennsylvania Smell Identification Test (UPSIT) score, and 22-item Sino-Nasal Outcome Test(SNOT-22) score. Primary analysis was conducted in the intention-to-treat population with screening blood eosinophil count (sBEC) ≥300 cells/uL. Safety data were evaluated in all patients.</p><p><strong>Results: </strong>Seventy-one patients were randomized (dupilumab, n = 38; placebo, n = 33). In the dupilumab group with sBEC≥300 cells/uL (n = 16), mean (95% CI) week 24 change from baseline in LMK-CT was -6.63 (-8.71 to -4.54); week 24 mean differences vs placebo (95% CI) for LMK-CT, sTSS, UPSIT, and SNOT-22 were -5.95 (-8.38 to -3.51), -1.43 ( 3.28 to 0.41), 5.91 (-1.56 to 13.38), and -14.71 (-34.35 to 4.94). Treatment-emergent adverse events were balanced between treatment groups.</p><p><strong>Conclusion: </strong>Dupilumab was associated with improvement in LMK-CT score and a trend toward improvement in sinonasal symptoms at week 24 in adults with severe, uncontrolled CRSsNP with sBEC ≥300 cells/uL.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"599-608"},"PeriodicalIF":5.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}